About the special issue
Biological therapies have revolutionized psoriasis treatment, and increased understanding of disease pathogenesis has yielded multiple therapeutic targets involving the IL-23/Th17 pathway. However, a lack of efficacy in select psoriasis patients, safety concerns and limited treatment efficacy in psoriasis variants are areas which still need improvement.
To show our commitment to this important field of research, Editorial Board Members Alan Menter and Steven Feldman are coordinating a best-in-class special issue on psoriasis in the winter of 2022. The issue will cover pathogenesis and therapeutic targets, therapeutic agents in clinical trials, disease comorbidity and pharmacoeconomics.
The editors are particularly keen to receive original research submissions to supplement an outstanding line-up of commissioned reviews and editorials.
If you are interested in contributing or would like to learn more, then please reach out to the Commissioning Editor, Alice Bough, who will be happy to assist.